Auro Laboratories Ltd. exhibits significant underperformance across almost all financial metrics compared to its peers. Companies like Sun Pharmaceutical Industries Ltd. and Cipla Ltd. lead the sector in profitability and growth, while Auro remains stagnant with zero growth and no return metrics. Auro's high PE ratio, in contrast to its growth, makes it less attractive as an investment, categorizing it as a financial risk compared to its outperforming peers.

• • Auro Laboratories shows no revenue growth and has a PE ratio of 73.36, indicating overvaluation given its stagnation.
• • Sun Pharmaceutical and Cipla are leaders in profitability metrics and revenue growth, suggesting strong operational efficiency.
• • Divi's Laboratories has a high PEG ratio, indicating potential overvaluation despite decent EPS growth.